Result: One or more of the non-TAMs, K65R/N, L74V/I, and Y115F were present in 1.4% (n = 3), 26% (n = 16), and 9.2% (n = 8) of patients receiving thymidine-analog, nonthymidine-analog, and both thymidine-analog and nonthymidine-analog regimens.
2014 Update of the drug resistance mutations in HIV-1.
Introduction: The following mutations have been added to existing classes or drugs: K65E/N has been added to the bars for the nucleoside and nucleotide analogue reverse transcriptase inhibitors (nRTIs) abacavir, didanosine, emtricitabine, lamivudine, stavudine, and tenofovir; L100I has been added to the bar for the nonnucleoside analogue reverse transcriptase inhibitor (NNRTI) rilpivirine; and F121Y has been added to the bars for the integrase strand transfer inhibitors (InSTIs) dolutegravir, elvitegravir, and raltegravir.
Discussion: Discussion: K65N gives an approximately 4-fold decrease in susceptibility.
Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens.
Result: (ii) K65N, which occurred in one patient receiving TDF; (iii) T69D, V75M, and V75T, which occurred in 1.3%, 2.5%, and 0.3% respectively; (iv) T215I occurred in 1.4% of patients; and (v) K219R and K219N, occurred in 1.6% and 0.9% respectively.
Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors.
PMID: 23749955
2013
The Journal of antimicrobial chemotherapy
Abstract: In addition to K65R (n = 395) and K65N (n = 9), another mutation, K65E, was found in 15 patients.
Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.
PMID: 23308370
2013
AIDS research and human retroviruses
Abstract: TAMs,>=3 TAMs, 69 insertion complex, K65R/N, and Q151M were observed in 43.0%, 10.6%, 18.3%, 2.8%, and 2.1% of the children, respectively.
A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1.
Abstract: RT processivity assays showed a significant decrease in the processivity of K65N RT in comparison to K65R RT.
Abstract: Analysis of RCs revealed a significant loss in replication (p=0.004) for viruses containing K65N mutation in comparison to those with K65R mutation.
Abstract: In addition to K65R, the other mutation observed at HIV-1 RT codon 65 is K65N.
Abstract: We demonstrated that the significant decrease in RC of K65N viruses is related to the impaired RT processivity of K65N
Primary HIV-1 drug resistance and polymorphic patterns among injecting drug users (IDUs) in Chennai, Southern India.
PMID: 19721100
2009
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill.
Abstract: RESULTS: M41LM (1.8%), K65KN (1.8%), and G73GS (2.7%) were found to be associated with low-level resistance to zidovudine (ZDV), stavudine (d4T), abacavir (ABC), didanosine (ddI), emtricitabine (FTC), tenofovir (TDF), and saquinavir (SQV) in each specimen.
[Study on genotypic resistance mutations to antiretroviral drugs on HIV strains of treated and treatment-naive HIV-1 infectious patients in Hubei province].
PMID: 18396668
2007
Zhonghua liu xing bing xue za zhi
Abstract: Some protease (PR) drug-resistant mutations were found in these samples, such as D30N (2.27%), D30G (2.27%), M46I (4.55%), M46N (2.27%), I47V (4.55%), I84V (4.55%), I84L (2.27%), N88S (2.27%) and L90S (2.27%) that all belonged to major drug-resistant but A71T (29.55%) belonged to minor resistance mutations Five treated patients were detected having mutations associated RT drug resistance: M41L (5.26%), A62V (5.26%),D67N (5.26%),
ViMRT
HIV mutation literature information.
PMID: 
2014
Viruses
